Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374201 | 1.00 | MEN1 (0.42) | MEN1KMT2AOPRM1OPRL1CNR2 | |
| SCHEMBL6092925 | 1.00 | MEN1 (0.42) | MEN1KMT2AOPRM1OPRL1CNR2 | |
| SCHEMBL5862048 | 1.00 | MEN1 (0.42) | MEN1KMT2AOPRM1OPRL1CNR2 | |
| SCHEMBL15630751 | 0.89 | AKT1 (0.41) | MEN1KMT2ARIPK1CTSSPTGES | |
| SCHEMBL17857495 | 0.89 | PDPK1 (0.36) | MEN1KMT2ARIPK1TRPM8PTGES | |
| SCHEMBL19305401 | 0.88 | OPRM1 (0.46) | MEN1KMT2AOPRM1OPRL1CNR2 | |
| SCHEMBL17724445 | 0.88 | OPRM1 (0.46) | MEN1KMT2AOPRM1OPRL1CNR2 | |
| SCHEMBL23523568 | 0.87 | BCHE (0.38) | TRPM8PTGES | |
| SCHEMBL23523571 | 0.87 | BCHE (0.38) | TRPM8PTGES | |
| SCHEMBL19518007 | 0.86 | MEN1 (0.48) | MEN1KMT2AOPRM1OPRL1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167048-A1 | N-4-piperidinyl compounds as ccr5 modulators | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20050171353-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| EP-1539695-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| WO-2004018425-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171353-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5) | CCR5, CXCR1, CCR7 | MEN1 4403/4885KMT2A 1493/4885OPRM1 59/4885 |
| US-20060167048-A1 | N-4-piperidinyl compounds as ccr5 modulators | CCR5, CCL5, CCR2 | MEN1 4212/4885KMT2A 2927/4885OPRM1 36/4885 |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CX3CR1 | MEN1 4852/4885KMT2A 4577/4885OPRM1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.